目的 观察和评价医用胶原蛋白海绵联合注射用血凝酶应用于混合痔术后的疗效和经济学优势。方法 将120例Ⅲ、Ⅳ度混合痔患者随机分为试验组、对照组、空白组三组,每组40例,分别行混合痔外剥内扎术,试验组采用医用胶原蛋白海绵联合注射用血凝酶止血,对照组采用可吸收止血膜止血,空白组采用普通纱条止血。观察、三组的止血效果、24 h出血量、术后感染情况、大便滴血时间、创面愈合时间、患者满意程度指标。结果 试验组、对照组两组有效率都为100 %。空白组有效率75 %。试验组的24 h出血量、术后感染情况、大便滴血时间、创面愈合时间均低于对照组与空白组,但不具有统计学意义(P>0.05)。满意度明显高于对照组及空白组,且具有统计学意义(P<0.01),三组均未出现术后感染。结论 医用胶原蛋白海绵联合巴曲亭具有良好的治疗效果和经济学优势,值得推广。
Objective To observe and evaluate the efficacy and economic advantages of medical collagen sponge combined with batroxobin in the treatment of mixed hemorrhoids. Methods A total of 120 patients with grade Ⅲ and Ⅳ mixed hemorrhoids were randomly divided into three groups: experimental group, control group, and blank group, with 40 cases in each group. After external dissection and internal ligation, the experimental group was treated with medical collagen sponge combined with batroxobin for hemostasis, the control group with absorbable hemostatic membrane, and the blank group with ordinary gauze. The hemostatic effect, 24 h blood loss amount, postoperative infection, stool bleeding time, wound healing time, and patients' satisfaction were recorded and analyzed. Results The effective rates of the experimental group and the control group were both 100%, and that of the blank group was 75%. The 24 h blood loss amount, postoperative infection incidence, stool bleeding time, and wound healing time of the experimental group were lower than those of the control group and the blank group(P>0.05), and the satisfaction score was significantly higher(P<0.01). No postoperative infection occurred in the three groups. Conclusion Medical collagen sponge combined with batroxobin has a satisfying therapeutic effect and economic advantages, which is worthy of promotion.
[1] 佘世昌. 混合痔治疗的研究进展[J].铜陵职业技术学院学报,2020,8(2):31-34
[2] 秦文祥,刘江文.高频电刀对重度混合痔手术创面愈合影响的研究[J].农垦医学,2017,39(5):400-402.
[3] 张玉兰,袁源,万星阳,等.可吸收止血膜止血作用的实验研究[J].中国医学物理学杂志,2017,34(8):841-847.
[4] 王丹,韩丽娟.医用胶原蛋白海绵在牙槽外科中的应用研究[J].全科口腔医学杂志,2018,5(30):9-11.
[5] 谭宝滢,任懋东,宣建伟.真实世界中注射用矛头蝮蛇血凝酶在外科应用的药物经济学[J].中国药物经济学,2020,15(3):11-14.